Nanovaccine for eliciting 10E8-like bnAbs against HIV-1
Document text
Principal Investigator: CHOWDA REDDY Organization: NEOVAXSYN, INC. Fiscal Year: 2021 Award: $300,000 Funding agency: National Institute of Allergy and Infectious Diseases Particle-based Co-delivery of HIV immunogens as Next-generation HIV Vaccines: Tailored immunogens (such as Envs, monomers, native and/or native-like trimers, nucleic acids/RNA such as mRNAs, self-amplifying RNAs) combined with an effective multivalent antigenic display on nanoparticles for delivery may provide a strategy to promote strong and long-lived neutralizing antibody responses against HIV and direct affinity maturation toward HIV neutralizing antibodies. The objective of this contract is to develop, evaluate, and optimize nanoparticle-based platforms to elicit broadly neutralizing antibodies against the membrane proximal external region (MPER) of the HIV-1 gp41 protein. Terms: <AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Affinity><Antibody Response><Antigens><Contracting Opportunities><Contracts><HIV><HIV vaccine><HIV-1><HIV-I><HIV/AIDS Vaccines><HIV1><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><LAV-HTLV-III><Lymphadenopathy-Associated Virus><Membrane><Messenger RNA><Non-Polyadenylated RNA><Nucleic Acids><Proteins><RNA><RNA Gene Products><RNA amplification><Ribonucleic Acid><Virus-HIV><base><human immunodeficiency virus vaccine><immunogen><mRNA><membrane structure><monomer><nano particle><nano particle delivery><nano vaccine><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><nanovaccine><neutralizing antibody><next generation><particle>